ALAUNOS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.32 USD | +13.79% |
|
+17.86% | +24.47% |
| 01/04 | Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 05/03 | North American Morning Briefing : S&P 500 Futures -2- | DJ |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 21.14M 1.76B |
|---|---|---|---|---|---|
| Net income 2024 * | -9M -750M | Net income 2025 * | - | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.2
x | P/E ratio 2025 * |
-
| Employees | 1 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.61% |
More Fundamentals
* Assessed data
More news
Latest transcript on Alaunos Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +13.79% | ||
| 1 week | +17.86% | ||
| Current month | -27.07% | ||
| 1 month | -30.16% | ||
| 3 months | -49.91% | ||
| 6 months | -13.56% | ||
| Current year | +24.47% |
1 week
0.98
1.34
1 month
0.981.89
Current year
0.983.29
1 year
0.6610.47
3 years
0.6660.15
5 years
0.66108.75
10 years
0.66223.95
| Managers | Title | Age | Since |
|---|---|---|---|
Dale Hogue
CEO | Chief Executive Officer | 54 | 29/12 |
| Director of Finance/CFO | 62 | 17/21/17 | |
Adam Levy
IRC | Investor Relations Contact | - | 01/20/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jaime Vieser
BRD | Director/Board Member | 54 | 16/20/16 |
Holger Weis
CHM | Chairman | 61 | 16/20/16 |
Robert Postma
BRD | Director/Board Member | 70 | 05/21/05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1.32 | +13.79% | 51,197 |
| 25/24/25 | 1.16 | -1.69% | 9,254 |
| 24/24/24 | 1.18 | -1.67% | 30,377 |
| 23/24/23 | 1.2 | +10.09% | 46,815 |
| 22/24/22 | 1.09 | -2.68% | 38,305 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology.
Calendar
09/05/2024
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.32
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.47% | 21.14M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- TCRT Stock
